According to ELN-risk groups, 130 patients had a favorable risk (CBF-AML, biallelic mutated CEBPA, mutant NPM1/FLT3-ITDneg) and 263 patients had no favorable risk. This evidence concerns the gene FLT3 and acute myeloid leukemia.